{
  "id": 10363007,
  "title": "IASO Bio reports 90 percent response rate for CAR T therapy",
  "url": "https://urgent.news/2026/09/28/iaso-bio-reports-90-percent-response-rate-for-car-t-therapy",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-28T04:41:20.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/iaso-bio-reports-90-percent-response-rate-for-car-t-therapy-161692.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "IASO Bio, a commercial-stage biopharmaceutical company focused on innovative cell therapies and biologics, has reported an impressive 90 percent response rate for its internally developed BCMA-targeted in vivo CAR-T cell therapy, IASO206. This data was presented at the 2026 International Myeloma Society (IMS) Annual Meeting by Dr. Wenqiang Yan of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. The FIH Phase 1 clinical trial enrolled patients with relapsed/refractory multiple myeloma (R/R MM) who had received at least two prior lines of therapy and had relapsed or refractory disease following treatment with proteasome inhibitors, immunomodulatory agents, and/or anti-CD38 antibodies. The trial evaluated three dose levels and demonstrated robust in vivo expansion of CAR-positive cells, as well as deep clinical responses, with 90% of patients achieving an objective response rate (ORR) and 90% having minimal residual disease (MRD) negativity. The safety profile of IASO206 was found to be manageable, with no dose-limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS), or treatment-related deaths reported.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Vietnam Investment Review",
        "title": "IASO Bio achieves 95 9 percent response rate in FUCASO study",
        "url": "https://urgent.news/2026/09/28/iaso-bio-achieves-95-9-percent-response-rate-in-fucaso-study",
        "published": "2026-09-28T04:36:28.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}